Darzalex 1800 mg is a groundbreaking monoclonal antibody treatment specifically designed for patients battling multiple myeloma, a complex and aggressive form of blood cancer. Manufactured by Janssen Pharmaceuticals, this innovative subcutaneous injection solution contains Daratumumab, a CD38-directed cytolytic antibody that has revolutionized multiple myeloma therapy. Darzalex has emerged as a preferred treatment globally due to its exceptional efficacy, patient convenience, and its significant role in improving survival rates in individuals with relapsed or refractory multiple myeloma.
Key Product Details:
- Active Ingredient: Daratumumab 1800 mg
- Form: Subcutaneous Injection Solution (SC)
- Administration: Subcutaneous (under the skin) use
- Packaging: 1 Vial (Flakon)
- Manufacturer: Janssen Pharmaceuticals
Benefits of Darzalex 1800 mg:
- Targeted CD38 Therapy: Effectively binds to CD38 protein on myeloma cells, inducing cell death through multiple immune-mediated mechanisms.
- Enhanced Survival Rates: Extends progression-free survival (PFS) and overall survival (OS) in patients with multiple myeloma.
- Subcutaneous Convenience: Faster administration compared to intravenous (IV) infusion, reducing treatment time and improving patient comfort.
- Combination Therapy: Demonstrates improved outcomes when combined with other anti-myeloma agents like lenalidomide, bortezomib, and dexamethasone.
- Reduced Infusion-Related Reactions: The subcutaneous formulation minimizes the risk of infusion-related side effects compared to the IV version.
How Does Darzalex 1800 mg Work?
Darzalex (Daratumumab) is an immunotherapy drug that targets the CD38 protein, which is highly expressed on multiple myeloma cells. Upon binding to CD38, Darzalex triggers multiple mechanisms of action, including:
- Antibody-Dependent Cellular Cytotoxicity (ADCC)
- Complement-Dependent Cytotoxicity (CDC)
- Antibody-Dependent Cellular Phagocytosis (ADCP)
Additionally, Daratumumab depletes immunosuppressive regulatory cells in the bone marrow, enhancing the body’s immune response against cancer cells.
Indications:
- Multiple Myeloma: Approved for newly diagnosed patients and those with relapsed or refractory multiple myeloma.
- Combination Regimens: Used alongside standard treatments such as lenalidomide, bortezomib, dexamethasone, and carfilzomib.
Dosage and Administration:
- Initial Dosing: Typically administered weekly during the first treatment cycle.
- Maintenance Phase: Administration frequency gradually reduces over time.
- Subcutaneous Injection: Administered under the skin, usually in the abdominal area, by a healthcare professional.
Safety and Side Effects:
- Common Side Effects: Fatigue, nausea, fever, upper respiratory tract infections, and injection site reactions.
- Severe Reactions: Infusion-related reactions are less common with the subcutaneous version but can still occur; close monitoring is necessary.
- Hepatitis B Reactivation: Screening is required before initiating therapy.
Why Choose Darzalex 1800 mg?
- Subcutaneous Innovation: Faster, more convenient administration with improved patient comfort.
- Proven Efficacy: Extensive clinical trials confirm Darzalex as a standard-of-care treatment for multiple myeloma.
- Comprehensive Therapy: Effective both as monotherapy and in combination with other anti-cancer agents.
- Global Recognition: Endorsed by leading oncology societies and widely prescribed across the world.
Storage Instructions:
- Temperature: Store in a refrigerator (2°C – 8°C). Do not freeze.
- Handling: Protect from light. Do not shake the vial.
Buy Darzalex 1800 mg Online:
Looking for a trusted source to purchase Darzalex 1800 mg (Daratumumab Subcutaneous Injection Solution)? We provide authentic Janssen products with reliable worldwide shipping. Secure your Darzalex supply today and access innovative multiple myeloma treatment solutions.
Değerlendirmeler
Henüz değerlendirme yapılmadı.